INAB
IN8bio, Inc.
Price Chart
Latest Quote
$1.48
| Previous Close | $1.48 |
| Open | $1.50 |
| Day High | $1.50 |
| Day Low | $1.47 |
| Volume | 1,681 |
Stock Information
| Shares Outstanding | 9.59M |
| Total Debt | $2.35M |
| Cash Equivalents | $21.94M |
| Net Income | $-18.98M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $14.19M |
| EPS (TTM) | $-2.54 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-5.01M |
| Income | $-18.98M |
| Book/sh | $2.31 |
| Cash/sh | $2.29 |
| Employees | 18 |
Financial Ratios
| Quick Ratio | 10.17 |
| Current Ratio | 10.50 |
| Debt/Eq | 10.33 |
Returns & Margins
| ROA | -52.75% |
| ROE | -103.55% |
Ownership
| Insider Ownership | 13.40% |
| Institutional Ownership | 38.12% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.40 |
| P/B | 0.64 |
Analyst Data
| Recommendation | none |
| Target Price | $6.25 |
Technical Indicators
| SMA20 | $1.51 |
| SMA50 | $1.53 |
| SMA200 | $1.81 |
| RSI | 43.18 |
| ATR | 0.0832 |
| Shares Float | 7.21M |
| Short Float | 1.22% |
| Short Ratio | 1.59 |
| Volatility | 0.19 |
| Rel Volume | 0.03 |
Performance History
| Week | +0.68% |
| Month | -12.43% |
| Quarter | -8.07% |
| 6 Months | -4.52% |
| YTD | -39.84% |
| Year | -33.93% |
| 3 Years | -97.51% |
| 10 Years | -99.51% |
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $1.48 | 1,681 |
| 2026-06-24 | $1.48 | 37,700 |
| 2026-06-23 | $1.46 | 15,400 |
| 2026-06-22 | $1.46 | 11,300 |
| 2026-06-18 | $1.43 | 52,900 |
| 2026-06-17 | $1.47 | 22,500 |
| 2026-06-16 | $1.38 | 40,500 |
| 2026-06-15 | $1.39 | 30,700 |
| 2026-06-12 | $1.43 | 11,100 |
| 2026-06-11 | $1.44 | 63,400 |
| 2026-06-10 | $1.40 | 37,700 |
| 2026-06-09 | $1.45 | 34,300 |
| 2026-06-08 | $1.44 | 26,400 |
| 2026-06-05 | $1.45 | 73,000 |
| 2026-06-04 | $1.54 | 37,900 |
| 2026-06-03 | $1.54 | 98,200 |
| 2026-06-02 | $1.56 | 108,800 |
| 2026-06-01 | $1.73 | 92,600 |
| 2026-05-29 | $1.87 | 93,000 |
| 2026-05-28 | $1.80 | 99,500 |
| 2026-05-27 | $1.80 | 84,000 |
| 2026-05-26 | $1.69 | 55,500 |
About IN8bio, Inc.
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $19,861,000 | $29,599,000 | $30,007,000 | $28,521,000 |
| Net Non Operating Interest Income Expense | $421,000 | $230,000 | $0 | - |
| Operating Expense | $19,861,000 | $29,599,000 | $30,007,000 | $28,521,000 |
| General And Administrative Expense | $9,650,000 | $12,637,000 | $13,510,000 | $14,459,000 |
| Other Income Expense | - | $-1,068,000 | $330,000 | - |
| Other Non Operating Income Expenses | - | - | $330,000 | - |
| Other Operating Expenses | - | - | $-330,000 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-19,440,000 | $-30,437,000 | $-30,007,000 | $-28,521,000 |
| Net Interest Income | $421,000 | $230,000 | $0 | - |
| Interest Income | $421,000 | $230,000 | $0 | - |
| Normalized Income | $-19,440,000 | $-29,369,000 | $-30,007,000 | $-28,521,000 |
| Net Income From Continuing And Discontinued Operation | $-19,440,000 | $-30,437,000 | $-30,007,000 | $-28,521,000 |
| Total Operating Income As Reported | $-19,440,000 | $-30,437,000 | $-30,007,000 | $-28,521,000 |
| Net Income Common Stockholders | $-19,440,000 | $-30,437,000 | $-30,007,000 | $-28,521,000 |
| Net Income | $-19,440,000 | $-30,437,000 | $-30,007,000 | $-28,521,000 |
| Net Income Including Noncontrolling Interests | $-19,440,000 | $-30,437,000 | $-30,007,000 | $-28,521,000 |
| Net Income Continuous Operations | $-19,440,000 | $-30,437,000 | $-30,007,000 | $-28,521,000 |
| Pretax Income | $-19,440,000 | $-30,437,000 | $-30,007,000 | $-28,521,000 |
| Special Income Charges | $0 | $-1,068,000 | $0 | - |
| Interest Income Non Operating | $421,000 | $230,000 | $0 | - |
| Operating Income | $-19,861,000 | $-29,599,000 | $-30,007,000 | $-28,521,000 |
| Per Share | ||||
| Diluted EPS | $-4.44 | $-17.05 | $-30.00 | $-40.80 |
| Basic EPS | $-4.44 | $-17.05 | $-30.00 | $-40.80 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-17,360,000 | $-25,876,000 | $-27,506,000 | $-27,418,000 |
| Total Unusual Items | $0 | $-1,068,000 | $0 | - |
| Total Unusual Items Excluding Goodwill | $0 | $-1,068,000 | $0 | - |
| Reconciled Depreciation | $2,501,000 | $2,655,000 | $2,501,000 | $1,103,000 |
| EBITDA (Bullshit earnings) | $-17,360,000 | $-26,944,000 | $-27,506,000 | $-27,418,000 |
| EBIT | $-19,861,000 | $-29,599,000 | $-30,007,000 | $-28,521,000 |
| Diluted Average Shares | $4,374,328 | $1,784,890 | $995,497 | $698,931 |
| Basic Average Shares | $4,374,328 | $1,784,890 | $995,497 | $698,931 |
| Diluted NI Availto Com Stockholders | $-19,440,000 | $-30,437,000 | $-30,007,000 | $-28,521,000 |
| Restructuring And Mergern Acquisition | $0 | $1,068,000 | $0 | - |
| Research And Development | $10,211,000 | $16,962,000 | $16,827,000 | $14,062,000 |
| Selling General And Administration | $9,650,000 | $12,637,000 | $13,510,000 | $14,459,000 |
| Other Gand A | $9,650,000 | $12,637,000 | $13,510,000 | $14,459,000 |
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $27,558,000 | $14,478,000 | $24,937,000 | $22,732,000 |
| Total Assets | $32,282,000 | $20,944,000 | $33,709,000 | $33,039,000 |
| Total Non Current Assets | $4,402,000 | $8,366,000 | $9,084,000 | $10,805,000 |
| Other Non Current Assets | $366,000 | $541,000 | $511,000 | $507,000 |
| Current Assets | $27,880,000 | $12,578,000 | $24,625,000 | $22,234,000 |
| Other Current Assets | $259,000 | $298,000 | $270,000 | $232,000 |
| Prepaid Assets | $529,000 | $1,160,000 | $3,073,000 | $3,820,000 |
| Cash Cash Equivalents And Short Term Investments | $27,092,000 | $11,120,000 | $21,282,000 | $18,182,000 |
| Cash And Cash Equivalents | $27,092,000 | $11,120,000 | $21,282,000 | $18,182,000 |
| Cash Financial | $27,092,000 | $11,120,000 | $21,282,000 | $18,182,000 |
| Goodwill And Other Intangible Assets | - | - | - | $126,000 |
| Other Intangible Assets | - | - | - | $126,000 |
| Non Current Deferred Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $2,782,000 | $5,030,000 | $4,893,000 | $5,874,000 |
| Long Term Debt And Capital Lease Obligation | $1,563,000 | $3,383,000 | $3,379,000 | $4,485,000 |
| Current Debt And Capital Lease Obligation | $1,219,000 | $1,647,000 | $1,514,000 | $1,389,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $4,724,000 | $6,466,000 | $8,772,000 | $10,307,000 |
| Total Non Current Liabilities Net Minority Interest | $1,563,000 | $3,383,000 | $3,379,000 | $4,485,000 |
| Current Liabilities | $3,161,000 | $3,083,000 | $5,393,000 | $5,822,000 |
| Payables And Accrued Expenses | $637,000 | $1,229,000 | $2,206,000 | $2,973,000 |
| Payables | $309,000 | $389,000 | $924,000 | $2,091,000 |
| Accounts Payable | $309,000 | $389,000 | $924,000 | $2,091,000 |
| Non Current Deferred Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $27,558,000 | $14,478,000 | $24,937,000 | $22,732,000 |
| Total Equity Gross Minority Interest | $27,558,000 | $14,478,000 | $24,937,000 | $22,732,000 |
| Stockholders Equity | $27,558,000 | $14,478,000 | $24,937,000 | $22,732,000 |
| Retained Earnings | $-141,096,000 | $-121,656,000 | $-91,219,000 | $-61,212,000 |
| Other | ||||
| Ordinary Shares Number | $9,766,132 | $2,416,108 | $1,442,910 | $818,171 |
| Share Issued | $9,766,132 | $2,416,108 | $1,442,910 | $818,171 |
| Tangible Book Value | $27,558,000 | $14,478,000 | $24,937,000 | $22,732,000 |
| Invested Capital | $27,558,000 | $14,478,000 | $24,937,000 | $22,732,000 |
| Working Capital | $24,719,000 | $9,495,000 | $19,232,000 | $16,412,000 |
| Capital Lease Obligations | $2,782,000 | $5,030,000 | $4,893,000 | $5,874,000 |
| Total Capitalization | $27,558,000 | $14,478,000 | $24,937,000 | $22,732,000 |
| Additional Paid In Capital | $168,644,000 | $136,127,000 | $116,152,000 | $83,941,000 |
| Capital Stock | $10,000 | $7,000 | $4,000 | $3,000 |
| Common Stock | $10,000 | $7,000 | $4,000 | $3,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $1,563,000 | $3,383,000 | $3,379,000 | $4,485,000 |
| Current Capital Lease Obligation | $1,219,000 | $1,647,000 | $1,514,000 | $1,389,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,305,000 | $207,000 | $1,673,000 | $1,460,000 |
| Current Accrued Expenses | $328,000 | $840,000 | $1,282,000 | $882,000 |
| Net PPE | $4,036,000 | $7,825,000 | $8,573,000 | $10,298,000 |
| Accumulated Depreciation | $-3,199,000 | $-2,263,000 | $-1,283,000 | $-321,000 |
| Gross PPE | $7,235,000 | $10,088,000 | $9,856,000 | $10,619,000 |
| Leases | $3,924,000 | $3,924,000 | $3,922,000 | $3,899,000 |
| Other Properties | $2,178,000 | $4,967,000 | $4,877,000 | $5,872,000 |
| Machinery Furniture Equipment | $1,133,000 | $1,197,000 | $875,000 | $819,000 |
| Properties | $0 | $0 | $0 | $0 |
| Construction In Progress | - | $0 | $182,000 | $29,000 |
| Treasury Shares Number | - | - | $0 | - |
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-12,712,000 | $-24,336,000 | $-23,940,000 | $-27,826,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-12,712,000 | $-24,149,000 | $-23,340,000 | $-24,121,000 |
| Cash Flow From Continuing Operating Activities | $-12,712,000 | $-24,149,000 | $-23,340,000 | $-24,121,000 |
| Operating Gains Losses | - | $45,000 | - | - |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $-187,000 | $-600,000 | $-3,705,000 |
| Cash Flow From Continuing Investing Activities | $0 | $-187,000 | $-600,000 | $-3,705,000 |
| Capital Expenditure | - | $-187,000 | $-600,000 | $-3,705,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $27,067,000 | $9,943,000 | $24,564,000 | $9,542,000 |
| Financing Cash Flow | $28,638,000 | $14,184,000 | $27,044,000 | $8,988,000 |
| Cash Flow From Continuing Financing Activities | $28,638,000 | $14,184,000 | $27,044,000 | $8,988,000 |
| Net Common Stock Issuance | $27,067,000 | $9,943,000 | $24,564,000 | $9,542,000 |
| Common Stock Issuance | $27,067,000 | $9,943,000 | $24,564,000 | $9,542,000 |
| Net Other Financing Charges | - | $-89,000 | - | - |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-693,000 | $-794,000 | $-798,000 | $-615,000 |
| End Cash Position | $27,092,000 | $11,120,000 | $21,282,000 | $18,182,000 |
| Other Cash Adjustment Outside Changein Cash | $-220,000 | $-266,000 | $-256,000 | - |
| Beginning Cash Position | $11,386,000 | $21,538,000 | $18,434,000 | $37,272,000 |
| Changes In Cash | $15,926,000 | $-10,152,000 | $3,104,000 | $-19,090,000 |
| Proceeds From Stock Option Exercised | $2,264,000 | $5,124,000 | $3,278,000 | $61,000 |
| Net Issuance Payments Of Debt | $-693,000 | $-794,000 | $-798,000 | $-615,000 |
| Net Long Term Debt Issuance | $-693,000 | $-794,000 | $-798,000 | $-615,000 |
| Long Term Debt Payments | $-693,000 | $-794,000 | $-798,000 | $-615,000 |
| Net PPE Purchase And Sale | $0 | $-187,000 | $-600,000 | $-3,705,000 |
| Purchase Of PPE | $0 | $-187,000 | $-600,000 | $-3,705,000 |
| Change In Working Capital | $1,038,000 | $-1,412,000 | $-204,000 | $-170,000 |
| Change In Other Current Liabilities | $-267,000 | $-838,000 | $-708,000 | $-414,000 |
| Change In Other Current Assets | $129,000 | $-20,000 | $0 | $-97,000 |
| Change In Payables And Accrued Expense | $506,000 | $-2,443,000 | $-185,000 | $2,434,000 |
| Change In Accrued Expense | $586,000 | $-1,908,000 | $796,000 | $924,000 |
| Change In Payable | $-80,000 | $-535,000 | $-981,000 | $1,510,000 |
| Change In Account Payable | $-80,000 | $-535,000 | $-981,000 | $1,510,000 |
| Change In Prepaid Assets | $670,000 | $1,889,000 | $689,000 | $-2,093,000 |
| Stock Based Compensation | $3,189,000 | $5,000,000 | $4,370,000 | $3,467,000 |
| Depreciation Amortization Depletion | $2,501,000 | $2,655,000 | $2,501,000 | $1,103,000 |
| Depreciation And Amortization | $2,501,000 | $2,655,000 | $2,501,000 | $1,103,000 |
| Depreciation | $2,501,000 | $2,655,000 | $2,501,000 | $1,103,000 |
| Gain Loss On Sale Of PPE | $0 | $45,000 | $0 | - |
| Net Income From Continuing Operations | $-19,440,000 | $-30,437,000 | $-30,007,000 | $-28,521,000 |
| Issuance Of Debt | - | - | - | - |
| Net Short Term Debt Issuance | - | - | - | - |
| Short Term Debt Payments | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |